Key result
Analysis of HuNoV genotypes showed that while 73.9% of antisera had weak or no cross-reactivity with heterologous genotypes, GII.5 antiserum cross-reacted with 30.4% of capsid P proteins.
Why the study?
Human norovirus has broad antigenic diversity, making the development of a broad-spectrum vaccine challenging.
HuNoV capsid P proteins show strong genotype-specific antigenicity; leaves open multivalent vaccine feasibility across 23 genotypes.
Human norovirus (HuNoV), which is the major causative agent of acute gastroenteritis, has broad antigenic diversity; thus, the development of a broad-spectrum vaccine is challenging. To establish the relationship between viral genetic diversity and antigenic diversity, capsid P proteins and antisera of seven GI and 16 GII HuNoV genotypes were analyzed. Enzyme-linked immunosorbent assays showed that HuNoV antisera strongly reacted with the homologous capsid P proteins (with titers > 5 × 104). However, 17 (73.9%) antisera had weak or no cross-reactivity with heterologous genotypes. Interestingly, the GII.5 antiserum cross-reacted with seven (30.4%) capsid P proteins (including pandemic genotypes GII.4 and GII.17), indicating its potential use for HuNoV vaccine development. Moreover, GI.2 and GI.6 antigens reacted widely with heterologous antisera (n ≥ 5). Sequence alignment and phylogenetic analyses of the P proteins revealed conserved regions, which may be responsible for the immune crossover reactivity observed. These findings may be helpful in identifying broad-spectrum epitopes with clinical value for the development of a future vaccine.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2021) studied Human norovirus (HuNoV) acute gastroenteritis. Capsid P proteins and antisera of seven GI and 16 GII HuNoV genotypes was evaluated on Cross-reactivity of HuNoV antisera with homologous and heterologous capsid P proteins. Analysis of HuNoV genotypes showed that while 73.9% of antisera had weak or no cross-reactivity with heterologous genotypes, GII.5 antiserum cross-reacted with 30.4% of capsid P proteins.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: